{"id":"https://openalex.org/W3111968028","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0219","title":"219 Long-term clinical outcomes associated with sequential treatment of BRAF mutant advanced melanoma patients","display_name":"219 Long-term clinical outcomes associated with sequential treatment of BRAF mutant advanced melanoma patients","publication_year":2020,"publication_date":"2020-11-01","ids":{"openalex":"https://openalex.org/W3111968028","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0219","mag":"3111968028"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2020-sitc2020.0219","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0219","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0219","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0219","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5020955148","display_name":"Ahmad A. Tarhini","orcid":"https://orcid.org/0000-0002-3193-9702","observed_orcids":["https://orcid.org/0000-0002-3193-9702"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ahmad Tarhini","raw_affiliation_strings":["Moffitt Comprehensive Cancer Center and Research Institute, Tampa, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Comprehensive Cancer Center and Research Institute, Tampa, FL, USA","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007052233","display_name":"David F. McDermott","orcid":"https://orcid.org/0000-0002-2675-5095","observed_orcids":["https://orcid.org/0000-0002-2675-5095","https://orcid.org/0000-0001-6978-0867"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David McDermott","raw_affiliation_strings":["Harvard Medical School; Beth Israel Deaconess Medical Center, Boston, MA, USA","Beth Israel Deaconess Medical Center, Boston, MA, USA","Harvard Medical School"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Harvard Medical School; Beth Israel Deaconess Medical Center, Boston, MA, USA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]},{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Boston, MA, USA","institution_ids":["https://openalex.org/I1316535847"]},{"raw_affiliation_string":"Harvard Medical School","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056195662","display_name":"Apoorva Ambavane","orcid":"https://orcid.org/0000-0001-5887-792X","observed_orcids":["https://orcid.org/0000-0001-5887-792X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Apoorva Ambavane","raw_affiliation_strings":["Evidera, London, MD, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evidera, London, MD, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000218289","display_name":"\u00c1gnes Benedict","orcid":"https://orcid.org/0000-0002-4747-4575","observed_orcids":["https://orcid.org/0000-0002-4747-4575"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Agnes Benedict","raw_affiliation_strings":["Evidera, London, MD, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evidera, London, MD, UK","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004017629","display_name":"Cho-Han Lee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cho-Han Lee","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084496300","display_name":"Corey Ritchings","orcid":"https://orcid.org/0000-0002-9240-9211","observed_orcids":["https://orcid.org/0000-0002-9240-9211"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Corey Ritchings","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001330237","display_name":"Brian D. Stwalley","orcid":"https://orcid.org/0009-0005-7313-045X","observed_orcids":["https://orcid.org/0009-0005-7313-045X"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian Stwalley","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017334876","display_name":"Meredith M. Regan","orcid":"https://orcid.org/0000-0002-2428-6109","observed_orcids":["https://orcid.org/0000-0002-2428-6109"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Meredith Regan","raw_affiliation_strings":["Harvard Medical School and Dana-Farber Cancer Institute, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Harvard Medical School and Dana-Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5052526230","display_name":"Michael B. Atkins","orcid":"https://orcid.org/0000-0003-3901-9924","observed_orcids":["https://orcid.org/0000-0003-3901-9924"]},"institutions":[{"id":"https://openalex.org/I4390039356","display_name":"Georgetown Lombardi Comprehensive Cancer Center","ror":"https://ror.org/035zrb927","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I184565670","https://openalex.org/I4390039356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Atkins","raw_affiliation_strings":["Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA","institution_ids":["https://openalex.org/I4390039356"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A130.2","last_page":"A131"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.8544999957084656,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.8544999957084656,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.09030000120401382,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.020800000056624413,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/treatment-sequencing","display_name":"treatment sequencing","score":0.6940000057220459},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.8769999742507935},{"id":"https://openalex.org/keywords/braf-mek-inhibitors","display_name":"BRAF/MEK inhibitors","score":0.8930000066757202},{"id":"https://openalex.org/keywords/anti-pd-1-antibody","display_name":"anti-PD-1","score":0.9459999799728394},{"id":"https://openalex.org/keywords/anti-ctla-4","display_name":"anti-CTLA-4","score":0.984000027179718},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8019999861717224},{"id":"https://openalex.org/keywords/life-years","display_name":"life-years","score":0.6610000133514404},{"id":"https://openalex.org/keywords/treatment-free-interval","display_name":"treatment-free interval","score":0.8989999890327454},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.453000009059906},{"id":"https://openalex.org/keywords/discrete-event-simulation","display_name":"discrete event simulation","score":0.8730000257492065},{"id":"https://openalex.org/keywords/matching-adjusted-indirect-comparison","display_name":"matching-adjusted indirect comparison","score":0.906000018119812},{"id":"https://openalex.org/keywords/checkmate-067","display_name":"CheckMate 067","score":0.8270000219345093}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6374068856239319},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6337660551071167},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.5518202185630798},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5333521366119385},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5175806283950806},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.45752274990081787},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.4337031841278076},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.24851387739181519},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1136/jitc-2020-sitc2020.0219","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0219","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0219","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"},{"id":"pmh:oai:doaj.org/article:e6af1d2b1dce4589af52cd09b5d7a922","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/e6af1d2b1dce4589af52cd09b5d7a922","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2020-sitc2020.0219","doi":"https://doi.org/10.1136/jitc-2020-sitc2020.0219","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2020-sitc2020.0219","pdf_url":null,"source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and young investigator award abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2890671599","https://openalex.org/W2904616511","https://openalex.org/W4312112970","https://openalex.org/W2345675440","https://openalex.org/W3166226934","https://openalex.org/W2549612601","https://openalex.org/W2791000413","https://openalex.org/W2613591752","https://openalex.org/W2990791869","https://openalex.org/W2170669390"],"abstract_inverted_index":{"Background":[0],"Patients":[1],"with":[2,11,23,111,146,153,168,196,199,209,219,229],"BRAF":[3,28],"mutant":[4,29],"advanced":[5,30],"melanoma":[6,31],"can":[7,108],"be":[8,109],"treated":[9],"sequentially":[10],"immunotherapies":[12],"(IO)":[13],"and":[14,103,121,159,189,276],"BRAF+MEK":[15,59,150,169],"inhibitors.":[16],"We":[17],"evaluated":[18],"the":[19,34,43,62,67,99,176,180,250,253,270,277],"clinical":[20,39,214,299,312],"outcomes":[21,78],"associated":[22,152],"various":[24,112],"treatment":[25,113,218,228],"sequences":[26,114,120,144,166,197],"for":[27,56,133,242,258],"based":[32,79],"on":[33,80,244,255,281],"5-year":[35,210],"follow-up":[36,64],"data":[37,82,124,211,280],"from":[38,83,139,212,302],"trials.":[40,87,313],"Methods":[41],"In":[42,205],"absence":[44,278],"of":[45,135,156,162,239,249,279,295,298],"head-to-head":[46],"trial":[47,274],"data,":[48],"a":[49,93,116,236,296],"matching-adjusted":[50],"indirect":[51],"comparison":[52],"(MAIC)":[53],"was":[54],"conducted":[55],"IO":[57,147,220,245],"vs.":[58,201],"inhibitors,":[60],"using":[61],"longest":[63],"available":[65],"in":[66,179,192,233,269,308],"published":[68,140,256],"literature.":[69,141],"Multivariate":[70],"risk":[71],"equations":[72,89],"were":[73,90,137,151,194],"developed":[74],"to":[75,97,225,263,266],"predict":[76],"time-to-event":[77],"patient-level":[81],"pooled":[84],"CheckMate-067":[85],"&-069":[86],"Risk":[88],"inserted":[91],"into":[92],"discrete":[94],"event":[95],"simulation":[96],"estimate":[98],"average":[100],"life-years":[101,105],"(LYs)":[102],"quality-adjusted":[104,163],"(QALYs)":[106],"that":[107],"gained":[110],"over":[115],"lifetime":[117],"horizon.":[118],"Treatment":[119,143],"corresponding":[122],"efficacy":[123],"sources":[125],"are":[126,252],"presented":[127],"below":[128],"(table":[129],"1).":[130],"Utility":[131],"weights":[132],"quality-adjustment":[134],"LYs":[136],"obtained":[138],"Results":[142],"starting":[145,167,198],"followed":[148,170],"by":[149,171],"2.9\u20134.3":[154],"years":[155,161],"additional":[157],"survival":[158,164,223,240],"2.2\u20133.3":[160],"versus":[165],"anti-PD-1.":[172],"After":[173],"1L":[174,217,227],"IO,":[175],"time":[177,190,241],"spent":[178,191,232],"treatment-free":[181],"interval":[182],"(TFI)":[183],"is":[184],"3.3\u20135.0":[185],"years.":[186],"LYs,":[187],"QALYs,":[188],"TFI":[193,234],"higher":[195],"anti-PD-1+anti-CTLA-4":[200],"anti-PD-1":[202],"alone.":[203],"Conclusions":[204],"this":[206,303],"sequencing":[207],"model":[208],"randomized":[213,311],"trials,":[215],"initiating":[216,226,246],"provided":[221],"prolonged":[222],"compared":[224],"BRAF+MEK.":[230],"Time":[231],"represents":[235],"significant":[237],"proportion":[238],"patients":[243],"sequences.":[247],"Limitations":[248],"study":[251],"reliance":[254],"information":[257],"BRAF+MEK,":[259],"which":[260],"could":[261],"lead":[262],"biases":[264],"due":[265],"unmeasured":[267],"differences":[268],"patient":[271],"populations":[272],"or":[273],"conduct":[275],"2L":[282],"combination":[283],"IO.":[284],"Anti-PD-1+anti-CTLA-4":[285],"as":[286],"second":[287],"line":[288],"option":[289],"has":[290],"not":[291],"been":[292],"included":[293],"because":[294],"lack":[297],"evidence.":[300],"Findings":[301],"analysis":[304],"will":[305],"require":[306],"validation":[307],"ongoing":[309],"prospective":[310]},"counts_by_year":[],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2020-12-21T00:00:00"}